Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at BMO Capital
November 8, 2018 8:56 AM ESTBMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $124.00) while maintaining a Outperform rating.
Kim commented, "We lower our estimates and target price to $116 from $124, following 3Q18 earnings that saw modest initial Onpattro sales... More
Alnylam Pharmaceuticals (ALNY) PT Lowered to $135 at Needham & Company
November 7, 2018 1:35 PM ESTNeedham & Company analyst Alan Carr lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $135.00 (from $152.00) while maintaining a Buy rating.
Carr commented, "Alnylam reported $0.5M in 3Q18 Onpattro sales, but mgmt noted that 125 U.S. patient start forms were submitted to Alnylam... More
